Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 32
Filter
1.
Pathol Oncol Res ; 27: 605017, 2021.
Article in English | MEDLINE | ID: mdl-34257567

ABSTRACT

Brain gliomas are characterized by remarkably intense invasive growth and the ability to create new blood vessels. Angiogenesis is a key process in the progression of these tumors. Coagulation and fibrinolysis factors play a role in promoting angiogenesis. The aim of the study was to evaluate the expression of proangiogenic proteins (VEGF and bFGF) and hemostatic proteins (TF, fibrinogen, fibrin, D-dimers) associated with neoplastic cells and vascular endothelial cells in brain gliomas of various degrees of malignancy. Immunohistochemical tests were performed using the ABC method with the use of mono- and polyclonal antibodies. The obtained results indicated that both neoplastic cells and vascular endothelial cells in gliomas of various degrees of malignancy are characterized by heterogeneous expression of proteins of the hemostatic system and angiogenesis markers. The strongest expression of proangiogenic factors and procoagulant factors was demonstrated in gliomas of higher-grade malignancy.


Subject(s)
Angiogenic Proteins/metabolism , Blood Coagulation Factors/metabolism , Brain Neoplasms/metabolism , Brain Neoplasms/pathology , Glioma/metabolism , Glioma/pathology , Humans , Neoplasm Grading , Neovascularization, Pathologic/metabolism
2.
Biomolecules ; 11(5)2021 04 29.
Article in English | MEDLINE | ID: mdl-33947134

ABSTRACT

Neoplastic processes are integrally related to disturbances in the mechanisms regulating hemostatic processes. Brain tumors, including gliomas, are neoplasms associated with a significantly increased risk of thromboembolic complications, affecting 20-30% of patients. As gliomas proliferate, they cause damage to the brain tissue and vascular structures, which leads to the release of procoagulant factors into the systemic circulation, and hence systemic activation of the blood coagulation system. Hypercoagulability in cancer patients may be, at least in part, a result of the inadequate activity of coagulation inhibitors. The aim of the study was to evaluate the expression of the inhibitors of the coagulation and fibrinolysis systems (tissue factor pathway inhibitor, TFPI; tissue factor pathway inhibitor-2 TFPI-2; protein C, PC; protein S, PS, thrombomodulin, TM; plasminogen activators inhibitor, PAI-1) in gliomas of varying degrees of malignancy. Immunohistochemical studies were performed on 40 gliomas, namely on 13 lower-grade (G2) gliomas (8 astrocytomas, 5 oligodendrogliomas) and 27 high-grade gliomas (G3-12 anaplastic astrocytomas, 4 anaplastic oligodendrogliomas; G4-11 glioblastomas). A strong expression of TFPI-2, PS, TM, PAI-1 was observed in lower-grade gliomas, while an intensive color immunohistochemical (IHC) reaction for the presence of TFPI antigens was detected in higher-grade gliomas. The presence of PC antigens was found in all gliomas. Prothrombin fragment 1+2 was observed in lower- and higher-grade gliomas reflecting local activation of blood coagulation. Differences in the expression of coagulation/fibrinolysis inhibitors in the tissues of gliomas with varying degrees of malignancy may be indicative of their altered role in gliomas, going beyond that of their functions in the hemostatic system.


Subject(s)
Blood Coagulation Factors/metabolism , Brain Neoplasms/pathology , Glioma/pathology , Thrombin/metabolism , Brain Neoplasms/metabolism , Female , Gene Expression Regulation, Neoplastic , Glioma/metabolism , Glycoproteins/metabolism , Humans , Male , Neoplasm Grading , Plasminogen Activator Inhibitor 1/metabolism , Protein C/metabolism , Protein S/metabolism , Thrombomodulin/metabolism
3.
In Vivo ; 33(3): 771-776, 2019.
Article in English | MEDLINE | ID: mdl-31028196

ABSTRACT

BACKGROUND/AIM: Hemostatic system components contribute to cancer progression independently from their roles in hemostasis. It has been shown that protein Z (PZ)/protein Z-dependent protease inhibitor (ZPI) inhibit coagulation factor X (FX). The aim of the study was to analyze the expression of PZ/ZPI in relation to the main coagulation factor - FX in human endometrial cancer tissue. MATERIALS AND METHODS: Immunohistochemical analysis was performed on 21 endometrial cancer specimens employing antibodies against ZPI, PZ and FX. RESULTS: Endometrial cancer cells showed a strong expression of ZPI and PZ and medium expression of FX. Normal endometrial tissue showed no expression of ZPI, PZ or FX. CONCLUSION: Strong expression of PZ and ZPI in endometrial cancer cells suggests a role of these proteins in endometrial cancer.


Subject(s)
Blood Proteins/metabolism , Endometrial Neoplasms/metabolism , Factor X/metabolism , Biomarkers , Endometrial Neoplasms/pathology , Female , Humans , Immunohistochemistry , Protein Binding , Protein Transport
4.
Adv Clin Exp Med ; 25(3): 505-11, 2016.
Article in English | MEDLINE | ID: mdl-27629739

ABSTRACT

BACKGROUND: Doxorubicin and docetaxel-based chemotherapy regimens used in breast cancer patients are associated with high risk of febrile neutropenia (FN). Granulocyte colony-stimulating factors (G-CSF) are recommended for both treating and preventing chemotherapy-induced neutropenia. Increased thrombosis incidence in G-CSF treated patients was reported; however, the underlying mechanisms remain unclear. The principal activator of blood coagulation in cancer is tissue factor (TF). It additionally contributes to cancer progression and stimulates angiogenesis. The main proangiogenic factor is vascular endothelial growth factor (VEGF). OBJECTIVES: The aim of the study was to evaluate granulocyte-colony stimulating factor receptor (G-CSFR), tissue factor (TF) expression and vascular endothelial growth factor receptor (VEGF-R) bound VEGF in human breast cancer in loco. MATERIAL AND METHODS: G-CSFR, TF and VEGFR bound VEGF (VEGF: VEGFR) were assessed in 28 breast cancer tissue samples. Immunohistochemical (IHC) methodologies according to ABC technique and double staining IHC procedure were employed utilizing antibodies against G-CSFR, TF and VEGF associated with VEGFR (VEGF: VEGFR). RESULTS: Expression of G-CSFR was demonstrated in 20 breast cancer tissue specimens (71%). In 6 cases (21%) the expression was strong (IRS 9-12). Strong expression of TF was observed in all investigated cases (100%). Moreover, expression of VEGF: VEGFR was visualized in cancer cells (IRS 5-8). No presence of G-CSFR, TF or VEGF: VEGFR was detected on healthy breast cells. Double staining IHC studies revealed co-localization of G-CSFR and TF, G-CSFR and VEGF: VEGFR, as well as TF and VEGF: VEGFR on breast cancer cells and ECs. CONCLUSIONS: The results of the study indicate that GCSFR, TF and VEGF: VEGFR expression as well as their co-expression might influence breast cancer biology, and may increase thromboembolic adverse events incidence.


Subject(s)
Breast Neoplasms/metabolism , Receptors, Granulocyte Colony-Stimulating Factor/metabolism , Receptors, Vascular Endothelial Growth Factor/metabolism , Thromboplastin/metabolism , Vascular Endothelial Growth Factor A/metabolism , Breast Neoplasms/pathology , Female , Humans , Immunohistochemistry , Protein Binding
5.
J BUON ; 20(6): 1426-31, 2015.
Article in English | MEDLINE | ID: mdl-26854437

ABSTRACT

PURPOSE: Erythropoiesis-stimulating agents (ESAs) are recommended for treating chemotherapy-induced anemia in breast cancer patients. Reduced survival rates in ESAs-treated patients have been reported, possibly due to thromboembolic complications, however the exact mechanism remains obscure. The principal activator of blood coagulation in cancer is tissue factor (TF). There are data that erythropoietin receptor (EPO-R) is expressed in tumor cells. The purpose of this study was to evaluate the expression of EPO-R and TF in loco in breast cancer. METHODS: The expression of EPO-R and TF was investigated in 24 invasive breast carcinoma specimens. Immunohistochemical (IHC) methodologies according to ABC technique and double-staining IHC procedure were employed utilizing antibodies against EPO-R and TF. RESULTS: Expression of EPO-R and TF was demonstrated in the tumor cells in all breast cancer specimens. No staining for EPO-R and TF was visualized in normal breast tissue. Double staining studies revealed co-expression of both EPO-R and TF in breast cancer cells and endothelial cells. CONCLUSIONS: EPO-R and TF expression and their coexpression in breast cancer cells suggest a possibility that EPO-R might be responsible for some adverse effects and reduced survival observed in ESAs-treated breast cancer patients with anemia, possibly due to the interaction with TF. Further experimental studies are warranted to determine the role of both EPO-R and TF in the treatment with ESAs of breast cancer patients with chemotherapy-induced anemia.


Subject(s)
Breast Neoplasms/chemistry , Receptors, Erythropoietin/analysis , Thromboplastin/analysis , Anemia/drug therapy , Breast Neoplasms/mortality , Female , Humans , Immunohistochemistry , Thromboembolism/etiology
6.
Ann Hematol ; 93(5): 779-84, 2014 May.
Article in English | MEDLINE | ID: mdl-24158387

ABSTRACT

In gastric cancer, hemostatic system components contribute to cancer progression, as activation of factor X (FX) was observed. The protein Z (PZ)/protein Z-dependent protease inhibitor (ZPI) complex inhibits factor Xa proteolytic activity. The purpose of this study was to determine the distribution of ZPI and PZ in relation to FX, and prothrombin fragment (F1 + 2), a standard marker for blood coagulation activation, in human gastric cancer tissue. ABC procedures and a double staining method employed polyclonal antibodies against PZ, FX, and F1 + 2 and a monoclonal antibody against ZPI. In situ hybridization (ISH) methods employed biotin-labeled 25-nucleotide single-stranded DNA probes directed to either PZ or ZPI mRNAs. FX and components of PZ/ZPI coagulation inhibitory system were observed in cancer cells. F1 + 2 was observed in gastric cancer cells as well. Double staining studies revealed FX/PZ, FX/ZPI, and PZ/ZPI co-localization on gastric cancer cells. ISH studies demonstrated the presence of PZ mRNA and ZPI mRNA in gastric cancer cells indicating induced synthesis of these proteins. The co-localization of PZ/ZPI and FX in gastric cancer cells indicates in loco that these proteins may play a role in anticoagulant events at the tumor tissue.


Subject(s)
Adenocarcinoma/genetics , Blood Proteins/genetics , Factor Xa/genetics , Gene Expression Regulation, Neoplastic , RNA, Messenger/genetics , Serpins/genetics , Stomach Neoplasms/genetics , Adenocarcinoma/metabolism , Adenocarcinoma/pathology , Blood Coagulation , Blood Proteins/metabolism , Disease Progression , Factor Xa/metabolism , Humans , Immunohistochemistry , In Situ Hybridization , Peptide Fragments/genetics , Peptide Fragments/metabolism , Protein Precursors/genetics , Protein Precursors/metabolism , Prothrombin/genetics , Prothrombin/metabolism , RNA, Messenger/metabolism , Serpins/metabolism , Stomach Neoplasms/metabolism , Stomach Neoplasms/pathology
7.
Folia Histochem Cytobiol ; 50(3): 375-80, 2012 Oct 08.
Article in English | MEDLINE | ID: mdl-23042267

ABSTRACT

The incidence of malignant gastrointestinal cancers in Poland has been constantly growing, which has led to an intensification of the search for new markers of the early clinical stage of this disease. The oral cavity,as the first part of the gastrointestinal tract, has a very important role. The oral cavity presents symptoms of both typically stomatological and systemic diseases. Oral cancers, benign or malignant, may originate and grow in any of the tissues of the mouth, and within this small area they may be of varied clinical, histological and biological features. These can be lesions typically observed in the oral cavity, but also characteristic of cases where the symptoms occur both in the mouth and in other body parts. The aim of this study was to present a cytological picture of the oral mucosa in patients with gastric and colon cancer and to compare the cytological picture with that obtained from a group of patients with no cancer, using the Papanicolaou classification and the Bethesda system. The study was conducted in 126 patients treated surgically in the II General and Gastroenterological Surgery Clinic between 2006 and 2008. All patients were divided into two groups based on the type of lesions. In both of the studied groups, more than half of the patients did not present any abnormalities in the mucosa of the mouth, lips and cheeks in the physical examination. None of the patients had erosion, ulceration or lesions typical of leukoplakia or lichen planus. No malignant cells were detected in either of the studied groups, and there were no well-defined lesions found in the oral cavity that would distinguish the patients with gastrointestinal cancer.


Subject(s)
Colonic Neoplasms/pathology , Mouth Mucosa/pathology , Stomach Neoplasms/pathology , Adult , Aged , Aged, 80 and over , Colonic Neoplasms/classification , Female , Humans , Immunohistochemistry , Male , Middle Aged , Staining and Labeling
8.
Thromb Res ; 129(4): e112-8, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22424030

ABSTRACT

INTRODUCTION: Several hemostatic system components, including factor X (FX), contribute to cancer progression. The Protein Z (PZ)/protein Z-dependent protease inhibitor (ZPI) complex directly inhibits factor Xa proteolytic activity. The aim of this study was to determine the antigenic distribution of ZPI and PZ, in relation to FX, as well as indicators of blood coagulation activation (F1+2 and fibrin) in human colon cancer tissue. MATERIALS & METHODS: Studies were performed on human colon cancer fragments. Immunohistochemical (IHC) ABC procedures and double staining method employed polyclonal antibodies against PZ, FX, F1+2 and monoclonal antibodies against ZPI and fibrin. In-situ hybridization (ISH) methods employed biotin-labeled 25-nucleotide single-stranded DNA probes directed to either FX, PZ or ZPI mRNAs. RESULTS: Expression of FX, PZ and ZPI in association with colon cancer cells was observed by IHC. Moreover, the presence of both F1+2 and fibrin in association with colon cancer cells was found, which indicates that blood coagulation activation proceeds extravascularly at the tumor site. Furthermore, expression of FX and PZ was visualized in association with endothelial cells. In turn, colon cancer-associated macrophages were characterized by FX , PZ and ZPI presence. The double staining studies revealed strong FX/PZ, FX/ZPI, as well as PZ/ZPI co-localization on colon cancer cells. ISH studies revealed the presence of FX mRNA, PZ mRNA and ZPI mRNA in colon cancer cells indicating induced synthesis of these proteins. CONCLUSIONS: The localization of PZ/ZPI and FX in colon cancer cells indicates that PZ/ZPI may contribute to anticoagulant events at the tumor site. Strong co-localization of PZ/ZPI and FX in cancer cells, and the presence of the mRNAs encoding the proteins, suggests their role in the tumor's biology. However, the presence of F1+2 and fibrin at the colon cancer site also suggests that the regulation of FXa by the PZ/ZPI complex at this site is incomplete.


Subject(s)
Blood Coagulation Factors/metabolism , Blood Proteins/metabolism , Colonic Neoplasms/metabolism , Hemostasis , Serpins/metabolism , Factor X , Humans , Tumor Cells, Cultured
9.
Thromb Res ; 129(4): e92-6, 2012 Apr.
Article in English | MEDLINE | ID: mdl-21975032

ABSTRACT

INTRODUCTION: NSCLC progression is often associated with VTE. Activation of factor X is an important step in blood coagulation activation in cancer patients. PZ)/ZPI contribute to direct factor Xa inhibition, and ZPI - attenuates factors IXa and XIa activity. The role of the PZ/ZPI in NSCLC is obscure. The aim of the study was to localize ZPI and PZ in NSCLC tissue in relation to factors X, IX and XI, as well as indicators of blood coagulation activation: prothrombin fragment F1+2 (F1+2) and fibrin. MATERIAL & METHODS: Immunohistochemical studies were performed on surgical NSCLC specimens employing antibodies against ZPI, PZ, coagulation factors X, IX, XI, as well as fibrinogen, F1+2 and fibrin. A semiquantitative analysis (acc. to immunoreactive score-IRS) was conducted. RESULTS: Medium expression of ZPI(IRS=6.5), together with weak expression of PZ(IRS=4), was observed in cancer cells. Strong or medium staining for factors IX, X, and XI(IRS=8-9) was revealed in cancer cells. Fibrinogen(IRS=10) and fibrin(IRS=8) were demonstrated in tumor stroma and cancer cells. F1+2(IRS=10) was localized in NSCLC cells. Endothelial cells (ECs) and tumor infiltrating macrophages (TAMs) were characterized by a positive staining for ZPI and PZ. CONCLUSIONS: ZPI and PZ expression in NSCLC cells, ECs and TAMs may suggest a role for PZ/ZPI in the anticoagulant mechanisms at the tumor site. The presence of F1+2 and fibrin, along with a disproportional expression of ZPI and PZ, might point to impaired function of the coagulation inhibitory system in NSCLC tissue.


Subject(s)
Blood Coagulation Factors/metabolism , Blood Proteins/metabolism , Carcinoma, Non-Small-Cell Lung/metabolism , Lung Neoplasms/metabolism , Serpins/metabolism , Humans , Tumor Cells, Cultured
10.
Anticancer Res ; 31(3): 843-7, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21498704

ABSTRACT

BACKGROUND: Colon cancer (CC) is frequently complicated by thromboembolic episodes. Thrombin plays a role in angiogenesis and among others induces the synthesis of vascular endothelial growth factor (VEGF) and its receptors (VEGFR-1 and VEGFR-2). The aim of this study was to assess the expression of prothrombin fragment F1+2 (F1+2), a byproduct in thrombin generation (indicating the presence of thrombin), in relation to the presence of VEGFR-2-bound VEGF (VEGF:VEGFR-2), as an indicator of VEGFR-2 activation in human CC tissue. MATERIALS AND METHODS: Immunohistochemical ABC and double staining studies were performed using antibodies against F1+2 and VEGF:VEGFR-2 in 59 specimens obtained from CC patients. RESULTS: Medium and high expression of both F1+2 and VEGF:VEGF2 in association with CC cells and endothelial cells was demonstrated. Moreover, coexpression of F1+2 and VEGF:VEGFR-2 was observed in the cells. CONCLUSION: The results may suggest a possible functional interaction between thrombin and VEGF-R2 stimulation in human CC in vivo.


Subject(s)
Colonic Neoplasms/metabolism , Peptide Fragments/metabolism , Prothrombin/metabolism , Vascular Endothelial Growth Factor A/metabolism , Vascular Endothelial Growth Factor Receptor-2/metabolism , Adult , Colonic Neoplasms/pathology , Female , Humans , Immunohistochemistry , Male , Middle Aged , Protein Transport
13.
Thromb Haemost ; 103(1): 198-204, 2010 Jan.
Article in English | MEDLINE | ID: mdl-20062932

ABSTRACT

Activation of blood coagulation, a phenomenon frequently observed in breast and colon cancer patients, contributes to tumour progression. The principal initiator of blood coagulation activation in cancer patients is tissue factor (TF), while tissue factor pathway inhibitor (TFPI) is the main inhibitor of the TF-dependent pathway of blood coagulation. Previous immunohistochemical studies revealed no expression of TFPI in human cancer cells. The aim of the study was to evaluate the expression of TFPI protein and mRNA in breast and colon cancer tissues. A total of 108 cancer tissues (from primary tumours and metastatic lymph nodes) were obtained from 87 patients during surgical treatment. Immunohistochemical studies using a polyclonal anti-TFPI antibody were performed including a semiquantitative analysis. The in situ hybridisation method employed single-stranded DNA oligonucleotide (probe sequence: 5'Biotin-CCACCATACTTGAAACGTTCACACT-Biotin3') directed against TFPI mRNA. Strong or medium expression of TFPI protein was observed in cancer cell bodies in all breast cancers and in most (39/66 cases) colon cancers examined. Weaker expression of TFPI was detected in cancer cells localised in lymph node metastatic foci of breast cancer. Endothelial cells were also TFPI-positive. TFPI mRNA was demonstrated in all cases of breast and in approximately 80% cases of colon cancer cells. TFPI mRNA and protein are present in association with colon and breast cancer cells, suggesting that the protein may play a role in cancer biology. The presence of TFPI in association with breast cancer cells localised in regional lymph nodes may indicate its role in lymphatic spread.


Subject(s)
Biomarkers, Tumor/analysis , Breast Neoplasms/chemistry , Colonic Neoplasms/chemistry , Lipoproteins/analysis , Biomarkers, Tumor/genetics , Breast Neoplasms/genetics , Breast Neoplasms/secondary , Colonic Neoplasms/genetics , Colonic Neoplasms/secondary , Female , Gene Expression Regulation, Neoplastic , Humans , Immunohistochemistry , In Situ Hybridization , Lipoproteins/genetics , Lymphatic Metastasis , Male , Neoplasm Staging , RNA, Messenger/analysis
14.
Thromb Res ; 125(3): e71-5, 2010 Mar.
Article in English | MEDLINE | ID: mdl-19818470

ABSTRACT

INTRODUCTION: Colorectal cancer (CRC) is often complicated by thromboembolic episodes. It has been recognized that blood coagulation proteins play a role in cancer progression. An important inhibitory mechanism is provided by the protein C (PC) system consisting of PC, protein S (PS) and thrombomodulin (TM). Recently, novel biological activities have been ascribed to the PC system that do not relate to their hemostatic functions, eg. in angiogenesis, apoptosis and inflammation. OBJECTIVES: The purpose of the study was to elucidate the solid phase interactions between CRC tissue and components of the PC system that may contribute to tumor progression. MATERIAL AND METHODS: CRC tissues were obtained at surgical resection during treatment of 66 patients. Immunohistochemical studies were performed using polyclonal antibodies against PC, PS and TM. A semiquantitative analysis of the protein expression was also performed. RESULTS: Weak expression of PC was observed in cancer cells of two-thirds of the specimens examined, while in 3/66 cases there was no staining for PC in cancer cells. One fourth of CRCs exhibited strong expression of PC. The presence of PS was demonstrated in 64/66 cases of CRC. However, its expression was irregular in terms of intensity of staining and percentage of cancer cells exhibiting protein expression. Weak expression of TM was demonstrated in two thirds of the cases examined, while a strong TM staining was revealed in one third of colon cancers. CONCLUSION: Heterogeneous expression of the PC system components in CRC tissue may point to their biological activity modulating tumor growth.


Subject(s)
Anticoagulants/metabolism , Colorectal Neoplasms/metabolism , Protein C/metabolism , Protein S/metabolism , Thrombomodulin/metabolism , Adult , Colorectal Neoplasms/pathology , Female , Humans , Immunohistochemistry , Male , Middle Aged
15.
Med Sci Monit ; 14(12): BR274-8, 2008 Dec.
Article in English | MEDLINE | ID: mdl-19043361

ABSTRACT

BACKGROUND: Glaucoma is a chronic neurodegeneration of the optic nerve and one of the leading causes of vision loss in the world among the aging. Recent data suggest an important role for Fas receptor- and caspase-3-mediated apoptosis in the pathophysiology of glaucoma. In this study, Fas receptor and caspase-3 immunoexpression in the optic nerve axons of eyeballs with absolute glaucoma and eyes enucleated following extensive trauma were compared. MATERIAL/METHODS: A series of 25 eyeballs were examined and enucleated during the period of 1994-2005. Seventeen eyeballs were removed from patients with absolute glaucoma who suffered from severe ophthalmalgia and 8 eyeballs were enucleated because of extensive injury on the day of injury or one day thereafter. The samples were obtained from the retrolaminar region of the optic nerve head and evaluated histopathologically. Immunohistochemistry was performed using polyclonal antibodies and the LSAB technique to determine Fas and caspase-3 expression. RESULTS: The percentages of positive Fas receptor and caspase-3 immunohistochemical staining were higher in the axons with absolute glaucoma than in the trauma group (p=0.0084 for Fas, p=0.0322 for caspase-3). CONCLUSIONS: The results indicate that the apoptosis markers Fas receptor and caspase-3 might play a significant role in glaucoma neuropathy at the stage of absolute glaucoma.


Subject(s)
Axons , Caspase 3/metabolism , Glaucoma/metabolism , Optic Nerve/metabolism , fas Receptor/metabolism , Adult , Aged , Aged, 80 and over , Apoptosis , Eye Enucleation , Female , Glaucoma/enzymology , Glaucoma/pathology , Humans , Immunohistochemistry , Male , Middle Aged , Optic Nerve/enzymology , Optic Nerve/pathology
16.
Folia Histochem Cytobiol ; 46(1): 69-72, 2008.
Article in English | MEDLINE | ID: mdl-18296266

ABSTRACT

Brain gliomas are characterized by invasive growth and neovascularisation potential. Angiogenesis plays a major role in the progression of gliomas and its determination has a great prognostic value. The aim of the study was to assess the vascularisation of chosen brain gliomas and to estimate how it is correlated with tumour histological type, malignancy grade, location and size, and with age and sex of patients. Tumour vascularisation analysis was based on the determination of microvascular proliferation (MVP) and microvessel density (MVD). Microvascular proliferation was measured with immunohistochemical methods using mouse monoclonal antibodies to detect cell proliferation antigens. The following antibodies were used Ki-67 and PCNA (DAKO). Identification of vessels was performed by CD31 antibody and anti-human von Willebrand factor (DAKO). The highest microvascular proliferation and microvascular density were observed in multiform glioblastomas and the lowest in oligodendrogliomas. Significant correlation was observed between the vascularisation and malignancy grade.


Subject(s)
Glioma/blood supply , Neovascularization, Pathologic/pathology , Adolescent , Adult , Aged , Aged, 80 and over , Cell Proliferation , Endothelial Cells/pathology , Female , Glioma/pathology , Humans , Immunohistochemistry , Male , Middle Aged , Oligodendroglioma/pathology
17.
J Clin Microbiol ; 44(9): 3448-51, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16954298

ABSTRACT

We demonstrated that not whole Mycobacterium tuberculosis but its particular antigens, hsp70(Mtb), hsp65(Mtb), and hsp16(Mtb), are present in lymph node tissues of patients with sarcoidosis (SA). hsp16(Mtb) occurs in the early stage of SA, whereas hsp70(Mtb) occurs in stage II of SA. hsp65(Mtb) is highly expressed in the capillary vessels in lymph node tissues in patients with SA.


Subject(s)
Bacterial Proteins/metabolism , Chaperonins/metabolism , HSP70 Heat-Shock Proteins/metabolism , Heat-Shock Proteins/metabolism , Lymph Nodes/metabolism , Mycobacterium tuberculosis/pathogenicity , Sarcoidosis, Pulmonary/diagnosis , Tuberculosis/diagnosis , Chaperonin 60 , Humans , Lymph Nodes/microbiology , Mycobacterium tuberculosis/metabolism , Sarcoidosis, Pulmonary/microbiology , Tuberculosis/microbiology
18.
Pol Merkur Lekarski ; 20(118): 462-7, 2006 Apr.
Article in Polish | MEDLINE | ID: mdl-16886577

ABSTRACT

UNLABELLED: Colon cancer morbidity in Poland is still increasing. During the course of the disease thromboembolic complications are often observed. It was documented that components of the hemostatic system influence cancer progression. The presence of coagulation factors was revealed in colon cancer tissue. So far the information on the presence of inhibitors of coagulation in this tumor type was lacking. The aim of the study was to evaluate the expression of coagulation inhibitors in loco in colon cancer. MATERIAL AND METHODS: Immunohistochemical method employing polyclonal antibodies directed against tissue factor pathway inhibitor (TFPI), antithrombin III (AT Ill), protein C (PC) and protein S (PS) was introduced. RESULTS: The presence of TFPI was observed in cancer cells in a part of examined specimens, but the intensity of the staining was different. In most cases of colon cancer AT III expression of low intensity was revealed in a few cancer foci. In approximately 15% of cases there was no AT Ill expression, while in other 15% of examined fragments of colon cancer AT Ill was readily detected. Weak expression of TM was observed in most colon cancer tissues, but only in some cancer foci. In 1/3 of examined cases the strong expression of TM was revealed. Weak and heterogeneous intensity of expression of PC was demonstrated in about 75% of colon cancer cases, whereas in about 25% of the specimens--the expression of this protein was strong. Furthermore in most cases there was no or weak expression of PS. Only in about 25% of the cases the staining for PS was strong. Expression of TFPI, AT III and PC was revealed in macrophages, whereas TFPI and AT Ill were detected in mucus in the lumen of neoplastic glands, and TM--in endothelial cells. CONCLUSIONS: Weak representation or the lack of coagulation inhibitors in colon cancer in most cases may facilitate coagulation activation in the tumor burden, and consequently promote colon cancer progression. Heterogeneous and inconstant presence of blood coagulation inhibitors in colon cancer in loco may suggest, that nonocoagulant biological activities of these inhibitors may influence the cancer growth or its inhibition in an individual patient. Obtained results suggest that introducing various forms of blood coagulation inhibitors in the treatment of colon cancer patients may be beneficial in selected group of patients.


Subject(s)
Anticoagulants/metabolism , Colonic Neoplasms/metabolism , Animals , Anticoagulants/therapeutic use , Antithrombin III/analysis , Colonic Neoplasms/drug therapy , Disease Progression , Humans , Immunohistochemistry , Lipoproteins/analysis , Protein C/analysis , Protein S/analysis
19.
Pathophysiol Haemost Thromb ; 34(1): 23-8, 2005.
Article in English | MEDLINE | ID: mdl-16293982

ABSTRACT

The aim of the study was to assess the expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) in neointima of polyester vascular grafts. Anastomotic areas were examined at 1, 4 and 12 months after prosthesis implantation in dogs, as well as in human vascular grafts. Immunohistochemistry was performed for uPA and uPAR. Graft neointima in dogs was positively stained for uPA with increased intensity at 4 and 12 months, whereas uPAR expression appeared at 4 and its intensity was increased at 12 months. Intensive uPA and positive uPAR labeling was shown in human grafts. The results demonstrated that in the early period of the healing process of polyester vascular grafts only uPA is present in the neointima in the region of the graft to adjacent artery anastomosis, whereas in healed grafts in dogs and humans uPAR is found as well.


Subject(s)
Blood Vessel Prosthesis , Receptors, Cell Surface/biosynthesis , Tunica Intima/metabolism , Urokinase-Type Plasminogen Activator/biosynthesis , Animals , Dogs , Female , Humans , Immunohistochemistry , Male , Receptors, Urokinase Plasminogen Activator , Tunica Intima/cytology
20.
Pol Merkur Lekarski ; 18(104): 176-9, 2005 Feb.
Article in Polish | MEDLINE | ID: mdl-17877125

ABSTRACT

Colorectal cancer is the third most often cause of morbidity and mortality due to cancer in Poland. Thromboembolic complications are common events during the course of the disease. It is well known that hemostatic proteins play an important role in cancer progression. The purpose of the study was to evaluate the in loco interactions among colorecatal cancer and coagulation factors. 21 cases of G2 colorectal adenocarcinoma obtained during surgical resection were examined. Immunohistochemical procedures according to ABC method were employed. Tissue factor (TF) and coagulation factors II, VII, X, IX were observed in cancer cells and except factors II and IX--in tumor associated macrophages. TF was also demonstrated in endothelial cells of small blood vessels. Strong expression of fibrinogen was observed among connective tissue at some distance around malignant tumor while weaker expression was found in tumor stroma. Expression of F(1+2), the by-product of thrombin generation, was revealed in cancer cells, macrophages and in the tumor stroma. The results indicate extravascular activation of blood coagulation in loco in colorectal cancer that is TF-dependent.


Subject(s)
Blood Coagulation Factors/metabolism , Blood Coagulation , Carcinoma/metabolism , Colorectal Neoplasms/metabolism , Blood Coagulation Factors/analysis , Carcinoma/blood supply , Colorectal Neoplasms/blood supply , Factor IXa/analysis , Factor VII/analysis , Factor X/analysis , Fibrin/analysis , Fibrinogen/analysis , Humans , Immunohistochemistry , Neovascularization, Pathologic , Prothrombin/analysis , Thromboplastin/analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...